Q-omics provides the consensus-scored GGN profile across patient tissues and cancer cell-line models. GGN expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GGN is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, GGN RNA expression shows 17,391 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, HNSC, and THYM as cancer lineages where GGN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GGN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GGN survival associations across molecular data types. GGN RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GGN RNA expression–survival associations across cancer types. High GGN expression shows unfavorable associations in MESO, KIRC, UVM, KIRP and LGG, but favorable associations in DLBC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GGN RNA expression.
This table summarizes GGN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GGN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GGN shows higher tumor expression in HNSC, LUAD, COAD, BLCA, LUSC and LIHC. The HNSC box plot shows higher GGN RNA expression in tumor versus normal tissue (log2 FC = +0.372, t-test p < 0.001).
This table shows molecular features associated with GGN in patient tissues and cancer cell lines. In patient samples, GGN shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GGN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
